A recent analysis of UM guidelines published between 2004 and 2019 appraised the methodological quality of assessed guidelines using AGREE II and AGREE-REX tools.1
Click here to access the full publication.
From Melanoma Res (2019) 29(6), 561-568. Used with permission.
CHT, conventional chemotherapy (fotemustine, treosulfan + gemcitabine, cisplatin + treosulfan + gemcitabine, dacarbazine, DHA-paclitaxel, or temozolomide + bevacizumab); CPI, checkpoint inhibitor (anti-CTLA4 antibody, anti–PD-1/anti–PD-L1 antibody).
While no approved therapy has demonstrated a substantial benefit specifically for patients with mUM,2,12 guidelines recommend a multidisciplinary approach to the management of metastatic disease.4,6,8,17
Multidisciplinary teams may include expertise from the following areas6,8,17:
Radiology and radiotherapy